Oral Tafenoquine Plus Standard of Care Versus Placebo Plus Standard of Care for Babesiosis
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT06207370 |
Recruitment Status :
Not yet recruiting
First Posted : January 17, 2024
Last Update Posted : March 15, 2024
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Babesiosis | Drug: Tafenoquine Other: Placebo | Phase 2 |
This study is a double-blind, randomized, multisite, placebo-controlled trial comparing the safety and efficacy of TQ versus placebo in patients hospitalized for babesiosis with low risk for relapsing disease who will also be administered a standard-of-care antimicrobial regimen (A/A) that is recommended in the 2020 IDSA guideline on the diagnosis and management of babesiosis.
Patients hospitalized for a diagnosis of babesiosis, who have received A/A for <48 hours (h) prior to randomization or are about to receive A/A, will be asked to provide written informed consent and will undergo eligibility screening including medical history, physical examination, prior and concomitant medications, blood chemistry and hematology, glucose-6-phosphate dehydrogenase (G6PD) deficiency testing, blood smear for diagnostic confirmation of babesiosis, pregnancy testing for females of child-bearing potential, and assessment of risk factors for relapsing babesiosis. The screening period will last a maximum of two days. The first day of dosing with TQ or placebo will be Day 1 and will be done while the patient is still hospitalized.
Study Type : | Interventional (Clinical Trial) |
Estimated Enrollment : | 33 participants |
Allocation: | Randomized |
Intervention Model: | Single Group Assignment |
Masking: | Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor) |
Masking Description: | Double blind |
Primary Purpose: | Treatment |
Official Title: | A Double-blind Placebo-controlled Study to Assess the Safety and Efficacy of Oral Tafenoquine Plus Standard of Care Versus Placebo Plus Standard of Care in Patients Hospitalized for Babesiosis |
Estimated Study Start Date : | May 1, 2024 |
Estimated Primary Completion Date : | March 1, 2025 |
Estimated Study Completion Date : | July 1, 2025 |
Arm | Intervention/treatment |
---|---|
Active Comparator: Group 1
TQ: 2 x 100 mg TQ tablets orally on Days 1, 2, 3, and 4
|
Drug: Tafenoquine
Oral Tafenoquine |
Placebo Comparator: Group 2
Placebo: 2 x 100 mg placebo tablets orally on Days 1, 2, 3, and 4
|
Other: Placebo
Placebo |
- Time to sustained clinical resolution [ Time Frame: Day 1 to 90 ]Time to sustained clinical resolution of all the following symptoms of babesiosis: sweats, joint aches, cough, loss of appetite, muscle aches, headache, chills or shivering, feeling hot or feverish, nausea, fatigue (low energy or tiredness), and vomiting. The time to achieve sustained clinical resolution will be the date when patients first self-report a 7-day period without these symptoms relative to the start of tafenoquine or placebo treatment.
- Difference in TTMC between TQ and placebo [ Time Frame: Day 1 to 90 ]Difference in TTMC between TQ and placebo from Day 1 to Day 90 (± 7 days). Molecular cure is defined as the time to the first instance of a negative NAT.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years and older (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Male or female, aged ≥ 18 years.
- Laboratory confirmed infection with Babesia.
- Exhibiting at least one self-reported clinical symptoms of babesiosis.
- Able and willing to give written informed consent.
- Expected to be hospitalized at the time of or following informed consent and still hospitalized on the day of randomization and start of investigational products.
- Willing to complete the study activities and assessments.
- Must agree not to enroll in another study of an investigational agent prior to completion of the study.
- Able to take oral medications.
- If female of reproductive age, must agree to use an acceptable method of birth control.
- Adequate venous access.
- Blood hemoglobin ≥ 7 g/dL.
Exclusion Criteria:
- Have any contraindications to TQ.
- Have any contraindication for azithromycin or atovaquone.
- Any concomitant significant illness unrelated to babesiosis.
- Receipt of any experimental treatment for babesiosis.
- Taking any excluded concomitant medication.
- Current or planned treatment with quinine while participating in the study.
- Positive pregnancy test.
- If A/A was initiated more than 48h prior to randomization and parasitemia is not >1%.
- Azithromycin or atovaquone administered in the last 12 months to treat babesiosis, and, in the opinion of the investigator, high likelihood that current infection represents a relapse or continuation of disease.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT06207370
Contact: Geoff Dow | 202-327-5422 | geoffdow@60degreespharma.com |
Responsible Party: | 60 Degrees Pharmaceuticals LLC |
ClinicalTrials.gov Identifier: | NCT06207370 |
Other Study ID Numbers: |
TQ-BA-2024-1 |
First Posted: | January 17, 2024 Key Record Dates |
Last Update Posted: | March 15, 2024 |
Last Verified: | December 2023 |
Individual Participant Data (IPD) Sharing Statement: | |
Plan to Share IPD: | No |
Studies a U.S. FDA-regulated Drug Product: | Yes |
Studies a U.S. FDA-regulated Device Product: | No |
babesiosis |
Babesiosis Protozoan Infections, Animal Parasitic Diseases, Animal Parasitic Diseases Infections Protozoan Infections Tick-Borne Diseases |
Vector Borne Diseases Tafenoquine Antimalarials Antiprotozoal Agents Antiparasitic Agents Anti-Infective Agents |